Related Experiment Videos
Mutations adjacent to the dimple of the canine parvovirus capsid structure affect sialic acid binding
D P Barbis1, S F Chang, C R Parrish
1James A. Baker Institute, New York State College of Veterinary Medicine, Cornell University, Ithaca 14853.
Abstract:
The erythrocyte receptor on rhesus macaque erythrocytes used by canine parvovirus (CPV) for binding in hemagglutination (HA) was examined. Erythrocyte membrane proteins were electrophoresed and blotted to nitrocellulose and probed with [125I]-labeled CPV capsids, showing seven virus-binding proteins. Treatment of erythrocytes or isolated membranes with Clostridium perfringens neuraminidase virtually abolished virus binding. Binding was also affected by treatment with potassium periodate and inhibited by wheat germ agglutinin, but was not significantly affected by concanavalin A, peanut agglutinin, or soluble N-acetyl-neuraminlactose. A non-HA mutant of CPV failed to bind to erythrocytes or to blotted erythrocyte membrane proteins. The mutation was a single Arg-Lys difference of VP2 amino acid residue 377. The pH dependence of binding of the closely related feline panleukopenia virus was shown to result from a decreased binding in buffers with pH values of 6.8 or greater. The VP2 residues responsible for that difference have been shown to be 323 and 375. The sequences affecting binding were all adjacent to the dimple in the capsid, implicating that region of the capsid as the sialic acid binding site. The role of sialic acid in virus-host cell interactions was not defined, but the plaque sizes of the non-HA mutant and wild type CPV were indistinguishable.
Insights
Canine parvovirus (CPV) uses sialic acid on rhesus macaque erythrocytes for binding, identified through protein analysis and viral mutants. This interaction is crucial for hemagglutination (HA) but doesn't affect viral plaque size.
Area of Science:
- Virology
- Molecular Biology
- Biochemistry
Background:
- Canine parvovirus (CPV) utilizes erythrocyte receptors for hemagglutination (HA).
- Understanding the specific viral-host interactions is key to viral pathogenesis.
Purpose of the Study:
- To identify the erythrocyte receptor utilized by CPV for hemagglutination.
- To investigate the role of specific viral capsid proteins in receptor binding.
Main Methods:
- Electrophoresis and blotting of erythrocyte membrane proteins.
- Probing with radiolabeled CPV capsids.
- Enzymatic and chemical treatments of erythrocytes and membranes.
- Analysis of non-hemagglutinating CPV mutants.
Main Results:
- Seven CPV-binding proteins were identified on erythrocyte membranes.
- Neuraminidase treatment abolished CPV binding, indicating sialic acid involvement.
- A single amino acid mutation (Arg-Lys at VP2 residue 377) in CPV abolished erythrocyte binding.
- Feline panleukopenia virus binding pH dependence was linked to VP2 residues 323 and 375.
- Binding sites are located near the capsid dimple, suggesting it's the sialic acid binding site.
Conclusions:
- Sialic acid on rhesus macaque erythrocytes is the primary receptor for CPV hemagglutination.
- Specific regions on the CPV capsid, particularly near the dimple, mediate sialic acid binding.
- While essential for HA, this binding interaction does not appear to influence CPV plaque size in vitro.